Dualogics LLC

Biotech · Private

Bispecific antibody immunotherapy for triple negative breast cancer using proprietary OrthoMab platform

dualogics.com →
Grants
$450K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Development of a Bispecific Antibody Based Immunotherapy for Triple Negative Breast Cancer$225,000
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Development of a Bispecific Antibody Based Immunotherapy for Triple Negative Breast Cancer$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3017MAA Laboratories Inc.——
3018GLYCOMANTRA INC——
3019AQUILUS PHARMACEUTICALS INC——
3020Dualogics LLC——
3021Deep Cell Industries Inc.—$771K
3022Nitrase Therapeutics——
3023EASCRA BIOTECH, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.